Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Net prices that health plans paid for medicines rose a modest 0.4% in the fourth quarter, but that compared unfavorably with ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due ...

Talks between CMS and drugmaker Amgen authorized under the Inflation Reduction Act (IRA), former President Biden's signature ...